Skip to content

PolitiKit

Lobbying by Centre for Commercialization of Regenerative Medicine: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Centre for Commercialization of Regenerative Medicine

Meetings this Parliament
1
With MPs
0
Since Nov 2021
1
Active registrations
1

Most recent reported meeting: Jul 31, 2026.

Registrations in effect

Consultant In effect since Jul 20, 2026 Receives government funding

Consultant Carys Baker of Sussex Strategy Group

Consultant lobbyists

  • Carys Baker

Institutions they may lobby: Business Development Bank of Canada (BDC), Export Development Canada (EDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), National Defence (DND), National Research Council (NRC), Prime Minister's Office (PMO), Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (1)
  • Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization.

Registration 945238-387187-1. Look it up in the official Registry

Reported meetings

Spreadsheet
  • Reported by Carys Baker · Consultant

    • Niloo Boroun · Director of International Policy, Finance Canada (FIN)
    Discussions with federal officials to seek funding support for the growth and international expansion of Canada's cell and gene therapy and regenerative medicine sector, including potential federal investment to scale domestic biomanufacturing capacity, strengthen supply chain resilience for critical medicines, and support Canada's continued leadership in advanced therapies research, development, and commercialization. Read more

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.